CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Using index funds to manage risk emphasizes broad diversification and low costs. These funds help smooth returns and reduce exposure to idiosyncratic losses.
27,240 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Thinking about should lockheed martin stock? This practical guide breaks down the defense giant’s outlook, key cataly...
Two stalwarts of the insurance world compete for a spot in a 2026 portfolio. This article breaks down Lincoln Nationa...
Sam Altman declined interview requests for a high-profile AI documentary. The director answered by creating a Sam Bot...
Latin American ETFs EWZ and EWW are leading a regional rally in 2026, powered by stronger commodity markets and a shi...
A fresh retirement-income blueprint uses a $1 million portfolio anchored by SCHD to target roughly $58,000 per year i...
When work gets intense, money decisions get louder. This article breaks down how intensity at work affects your budge...
A high-yield ETF promises sky-high payouts but posted negative returns over the last year as investors weigh the true...
Andreessen Horowitz’s crypto arm is raising its fifth fund, aiming about $2 billion with a close planned for mid-2026...
Ethereum traders are watching a bold price target amid a tightening on-chain supply and growing institutional interes...
Old homes are cash machines for savvy flippers, but growing bureaucratic delays complicate rehab plans. Learn where r...
Markets brace for a potential rate move at the July FOMC meeting as JPMorgan Asset Management weighs in on Warsh-era ...